Extreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancer.
Gee
Julia M W
JM
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, CF10 3XF, Wales, UK. gee@cardiff.ac.uk
Giles
Martin G
MG
Nicholson
Robert I
RI
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D003593:Cytoplasm / Q000737:chemistry / Q000201:enzymology; D004789:Enzyme Activation / Q000502:physiology; D047628:Estrogen Receptor alpha; D006133:Growth Substances / Q000378:metabolism*; D048370:MAP Kinase Kinase 2; D048052:Mitogen-Activated Protein Kinase 3; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*; D013379:Substrate Specificity
D047628:Estrogen Receptor alpha; D006133:Growth Substances; D016328:NF-kappa B; D011960:Receptors, Estrogen; D011505:Protein-Tyrosine Kinases; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases; D048370:MAP Kinase Kinase 2; D020929:Mitogen-Activated Protein Kinase Kinases